Par Specialty Pharmaceuticals, a division of Par Pharmaceutical, Inc., announced the launch of Cortisporin-TC otic suspension (colistin sulfate - neomycin sulfate - thonzonium bromide - hydrocortisone acetate otic suspension).  

Cortisporin-TC otic suspension is indicated for the treatment of superficial bacterial infections of the external auditory canal (otitis externa), caused by organisms susceptible to the action of the antibiotics; and for the treatment of infections of mastoidectomy and fenestration cavities, caused by organisms susceptible to the antibiotics.  Cortisporin-TC otic suspension is the only treatment for otitis externa that contains thonzonium bromide, an ingredient that penetrates discharge to allow colistin (polymixin E), neomycin, and hydrocortisone to contact infected tissue.

"The Par Specialty sales force will build greater awareness of a product that has long been a trusted remedy for outer ear infections, also known as swimmer's ear," said Paul V. Campanelli, chief executive officer of Par Pharmaceutical Companies, Inc.  "Therefore, the launch of Cortisporin-TC has been timed to coincide with the traditional start of summer, Memorial Day weekend."

Otitis externa is inflammation of the external ear canal, which is the tube between the outer ear and eardrum, and can often be infected.  Otitis externa is often referred to as "swimmer's ear" because repeated exposure to water can make the ear canal more vulnerable to inflammation.

Cortisporin-TC otic suspension is supplied in a 10 mL bottle.  A sterilized dropper-cap assembly for use on the bottle of suspension is included in the package.

Par is a specialty pharmaceutical company that develops, manufactures and markets safe, innovative and cost-effective pharmaceuticals that help improve patient quality of life.